RxDoctor Payments Data

Andrew Gaffney

Physician Assistant · Albuquerque, NMNPI 1023367588

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,588 of the $4,290 with a category attached, or 83.6%. 15 manufacturers reported payments, led by Boston Scientific at 36.9% of the total. 2025 is the largest year on record at $2,197, 4.7 times the $470 reported in 2021. Among physician assistant clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,290in general payments, 2019–2025

Across 129 payments — averaging $33.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$710
  • Pfizer$324
  • Johnson & Johnson$321
  • Sanofi-aventis U.S. LLC$274
  • Cvrx, Inc.$252
  • plus $825 from 9 others

What the payments were for

  • Travel & lodging$70216%
  • Food & beverage$3,58884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,290 in reported general payments places this provider in the 95th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$254,127
XareltoRivaroxaban154$176,681
Dofetilide193$42,606
Flecainide Acetate165$5,785
Metoprolol Succinate194$3,117
Propafenone Hcl ErPropafenone Hcl11$2,721
Amiodarone Hcl128$2,045
Diltiazem 24hr Er (Cd)Diltiazem Hcl48$1,502
SotalolSotalol Hcl70$1,496
Metoprolol Tartrate75$593
Carvedilol49$499
ClopidogrelClopidogrel Bisulfate34$409
Atorvastatin Calcium31$387
Verapamil ErVerapamil Hcl12$347
Digoxin16$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$324$254,127238 claims
Johnson & JohnsonXarelto$321$176,681154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →